29
total announcements
AKUMS.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 15 Oct 2026
Market Cap
₹11,788 Cr
P/E (TTM)
40.4
P/E (Forward)
22.6
EPS (TTM)
₹19.05
52W Low
₹409.30
52W High
₹838.80
Dividend Yield
0.13%
Beta
0.56
Price / Book
3.6
Debt / Equity
5.8
Revenue (TTM)
₹4,504 Cr
Gross Margin
41.09%
Operating Margin
11.45%
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has received a Demand Notice from National Pharmaceutical Pricing Authority for manufacturing and marketing a new drug/formulation without prior price approval, resulting in a total demand of Rs. 52,74,68,193/-.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has received a certificate from MUFG Intime India Private Limited confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September, 2026.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has closed its trading window for insiders due to the upcoming announcement of its un-audited financial results for the quarter ending September 30, 2026.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has informed the Exchange about the schedule of institutional investors meets on 28th and 29th September 2026.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has informed the Exchange about a scheduled investor/analysts meet on September 22, 2026, at the Taj, Santacruz, Mumbai. The meet is part of the G200 Summit 2026, and no unpublished price-sensitive information will be shared.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has received an ESG rating of '65' for the Financial Year 2025-26 from NSE Sustainability Ratings & Analytics Limited, a subsidiary of NSE Indices Limited.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has informed the Exchange about the schedule of an investor/analysts meet on September 2, 2026, at Hyatt, Santacruz East, Mumbai.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has cancelled its participation in an Investor/Analysts Meet on August 25, 2026, due to medical reasons.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has informed the Exchange about the schedule of an investor/analysts meet on August 25, 2026, at Trident, BKC, Mumbai.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has informed the Exchange about the transcript of the investors/analysts conference call held on August 10, 2026, for the unaudited financial results of Q1 FY 27.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has informed the Exchange about the schedule of an investor/analysts meet on August 14, 2026, at Grand Hyatt, India, and will not share any unpublished price sensitive information during the meet.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has informed the Exchange about the link of recording of Investors/Analysts Conference Call held for the un-audited financial results for the quarter ended June 30, 2026.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has published its un-audited financial results for the quarter ended June 30, 2026, as approved by the Board of Directors. The results are available on the company's website and through a Quick Response (QR) Code in newspaper advertisements.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, detailing the utilization of proceeds from its Initial Public Offer (IPO). The report, issued by CRISIL Ratings Limited, Monitoring Agency, indicates that the company has not deviated from the objects of the issue.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Presentation for Q1 FY27 Investor Meet/Con. Call Updates. The company has registered a healthy revenue growth of over 13% with EBIDTA increasing by more than 30%. The acquisition of Oriflame India's Manufacturing business is expected to expand the company's manufacturing footprint in skincare cosmetics and wellness products.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has reported a 13.9% YoY revenue growth in Q1 FY27, with operating revenue of ₹1,167 crore and PAT of ₹101 crore.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding 'Un-audited Financial Results for the Quarter ended 30th June, 2026'. The Board of Directors has considered and approved the Un-audited (Standalone & Consolidated) Financial Results of the Company for the quarter ended June 30, 2026, along with the Limited Review Reports thereon.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, along with the Limited Review Reports from the Statutory Auditors, Walker Chandiok & Co LLP. The results are available on the company's website.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has informed the Exchange about the schedule of an investor/analysts conference call for Q1 FY 27 un-audited financial results.
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited has announced the acquisition of Oriflame India's manufacturing business for INR 56 Crore. The acquisition includes two manufacturing plants and a leased warehouse, marking Akums' entry into the color cosmetics market and expanding its presence in skincare & wellness products.